Iran's drug subsidy reform: do the sick really benefit?

Iran's drug subsidy reform: do the sick really benefit?

Iran’s ambitious effort to overhaul how prescription medicines are subsidized—shifting billions in support from cheap foreign currency allocations to insurance-based coverage—has delivered some gains but remains hamstrung by unstable financing, fragmented governance, and weak coordination among the agencies that must make it work, according to a new qualitative study published in the International Journal for […]